These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 30026269)
1. Direct Targeting of the mTOR (Mammalian Target of Rapamycin) Kinase Improves Endothelial Permeability in Drug-Eluting Stents-Brief Report. Harari E; Guo L; Smith SL; Paek KH; Fernandez R; Sakamoto A; Mori H; Kutyna MD; Habib A; Torii S; Cornelissen A; Jinnouchi H; Gupta A; Kolodgie FD; Virmani R; Finn AV Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):2217-2224. PubMed ID: 30026269 [TBL] [Abstract][Full Text] [Related]
2. Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-α activation and disruption of the p120-vascular endothelial cadherin interaction. Habib A; Karmali V; Polavarapu R; Akahori H; Cheng Q; Pachura K; Kolodgie FD; Finn AV Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2425-31. PubMed ID: 23887639 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Endothelial Barrier Functional Recovery After Implantation of a Novel Biodegradable-Polymer Sirolimus-Eluting Stent in Comparison to Durable- and Biodegradable-Polymer Everolimus-Eluting Stents. Sakamoto A; Torii S; Jinnouchi H; Guo L; Cornelissen A; Kuntz S; Cheng Q; Fernandez R; Paek KH; Harris K; Srivastava MC; Kolodgie FD; Virmani R; Finn AV Cardiovasc Revasc Med; 2021 Mar; 24():1-10. PubMed ID: 32928693 [TBL] [Abstract][Full Text] [Related]
4. Endothelial Barrier Protein Expression in Biodegradable Polymer Sirolimus-Eluting Versus Durable Polymer Everolimus-Eluting Metallic Stents. Mori H; Cheng Q; Lutter C; Smith S; Guo L; Kutyna M; Torii S; Harari E; Acampado E; Joner M; Kolodgie FD; Virmani R; Finn AV JACC Cardiovasc Interv; 2017 Dec; 10(23):2375-2387. PubMed ID: 29102583 [TBL] [Abstract][Full Text] [Related]
5. Stent coated with antibody against vascular endothelial-cadherin captures endothelial progenitor cells, accelerates re-endothelialization, and reduces neointimal formation. Lim WH; Seo WW; Choe W; Kang CK; Park J; Cho HJ; Kyeong S; Hur J; Yang HM; Cho HJ; Lee YS; Kim HS Arterioscler Thromb Vasc Biol; 2011 Dec; 31(12):2798-805. PubMed ID: 22015656 [TBL] [Abstract][Full Text] [Related]
6. PKCα activation of p120-catenin serine 879 phospho-switch disassembles VE-cadherin junctions and disrupts vascular integrity. Vandenbroucke St Amant E; Tauseef M; Vogel SM; Gao XP; Mehta D; Komarova YA; Malik AB Circ Res; 2012 Aug; 111(6):739-49. PubMed ID: 22798526 [TBL] [Abstract][Full Text] [Related]
7. Advances in mammalian target of rapamycin kinase inhibitors: application to devices used in the treatment of coronary artery disease. Jinnouchi H; Guo L; Sakamoto A; Sato Y; Cornelissen A; Kawakami R; Mori M; Torii S; Kuntz S; Harari E; Mori H; Fuller D; Gadhoke N; Fernandez R; Paek KH; Surve D; Romero M; Kolodgie FD; Virmani R; Finn AV Future Med Chem; 2020 Jun; 12(12):1181-1195. PubMed ID: 32431177 [TBL] [Abstract][Full Text] [Related]
8. Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation. Habib A; Karmali V; Polavarapu R; Akahori H; Nakano M; Yazdani S; Otsuka F; Pachura K; Davis T; Narula J; Kolodgie FD; Virmani R; Finn AV J Am Coll Cardiol; 2013 Mar; 61(9):971-80. PubMed ID: 23449430 [TBL] [Abstract][Full Text] [Related]
9. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Martinet W; De Loof H; De Meyer GRY Atherosclerosis; 2014 Apr; 233(2):601-607. PubMed ID: 24534455 [TBL] [Abstract][Full Text] [Related]
10. Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation. Finn AV; John M; Nakazawa G; Polavarapu R; Karmali V; Xu X; Cheng Q; Davis T; Raghunathan C; Acampado E; Ezell T; Lajoie S; Eppihimer M; Kolodgie FD; Virmani R; Gold HK Circ Res; 2009 Nov; 105(10):1003-12. PubMed ID: 19797172 [TBL] [Abstract][Full Text] [Related]
11. IRF-1 mediates the suppressive effects of mTOR inhibition on arterial endothelium. Peng K; Fan X; Li Q; Wang Y; Chen X; Xiao P; Passerini AG; Simon SI; Sun C J Mol Cell Cardiol; 2020 Mar; 140():30-41. PubMed ID: 32087218 [TBL] [Abstract][Full Text] [Related]
12. Everolimus-eluting stents improve vascular response in a diabetic animal model. Habib A; Karmali V; John MC; Polavarapu R; Nakazawa G; Pachura K; Davis T; Kolodgie FD; Virmani R; Finn AV Circ Cardiovasc Interv; 2014 Aug; 7(4):526-32. PubMed ID: 24915972 [TBL] [Abstract][Full Text] [Related]
13. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419 [TBL] [Abstract][Full Text] [Related]
14. Everolimus-induced hyperpermeability of endothelial cells causes lung injury. Chen X; Chen J; Liu S; Li X Exp Biol Med (Maywood); 2023 Dec; 248(23):2440-2448. PubMed ID: 38158699 [TBL] [Abstract][Full Text] [Related]
15. Metformin impairs endothelialization after placement of newer generation drug eluting stents. Habib A; Karmali V; Polavarapu R; Akahori H; Pachura K; Finn AV Atherosclerosis; 2013 Aug; 229(2):385-7. PubMed ID: 23880192 [TBL] [Abstract][Full Text] [Related]
16. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. Bangalore S; Toklu B; Amoroso N; Fusaro M; Kumar S; Hannan EL; Faxon DP; Feit F BMJ; 2013 Nov; 347():f6625. PubMed ID: 24212107 [TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells. Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial. Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; Otaegui I; Masotti M; Zueco J; Veláquez M; Sanchís J; García-Touchard A; Lázaro-García R; Moreu J; Bethencourt A; Cuesta J; Rivero F; Cárdenas A; Gonzalo N; Jiménez-Quevedo P; Fernández C; JACC Cardiovasc Interv; 2016 Jun; 9(12):1246-1255. PubMed ID: 27339840 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the endothelial coverage in everolimus and zotarolimus-eluting stents in normal, atherosclerotic, and bifurcation rabbit iliac arteries. Torii S; Nakazawa G; Ijichi T; Yoshikawa A; Ohno Y; Ikari Y Cardiovasc Interv Ther; 2018 Jan; 33(1):55-61. PubMed ID: 27822890 [TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of VE-cadherin controls endothelial phenotypes via p120-catenin coupling and Rac1 activation. Hatanaka K; Simons M; Murakami M Am J Physiol Heart Circ Physiol; 2011 Jan; 300(1):H162-72. PubMed ID: 21037229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]